Waylis Therapeutics

Executive Summary

Waylis Therapeutics is a US-based private biopharmaceutical company founded in 2018, with headquarters in Rahway, New Jersey, and operations in San Diego. The company focuses on developing small molecule therapeutics that target protein-protein interactions (PPIs) for oncology and other diseases. Additionally, it appears to have a commercial or patient access arm for generic or previously approved products, suggesting a dual strategy of innovation and access. Despite its 2018 founding, the company remains early-stage with no disclosed pipeline details, financials, or clinical data. The PPI targeting approach is a promising but challenging modality, and the generic arm may provide near-term revenue opportunities. However, the lack of publicly available information limits overall visibility, making it difficult to assess progress or competitive positioning.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead PPI Program20% success
• Q4 2026Strategic Partnership for Generic Product Launch30% success
• Q3 2026Series A Financing Completion40% success